CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
谁来监督监督者：T 细胞重定向疗法在 T 细胞恶性肿瘤中面临的独特挑战
英文原题：Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies.
查看英文原题
Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
新型T细胞重定向免疫疗法的发展——包括免疫检查点抑制剂、双特异性抗体、CAR-T 细胞和病毒特异性T细胞——代表了血液系统恶性肿瘤治疗的重大进步。尽管此类疗法在治疗B细胞肿瘤方面有强有力的疗效证据，但在使用这些疗法治疗T细胞恶性肿瘤时会遇到若干独特挑战。在本综述中，我们讨论T细胞调节性免疫疗法在T细胞肿瘤中的应用，重点关注疾病发病机制中恶性T细胞与旁观者T细胞之间复杂的双向相互作用，以及由此产生的、影响该人群T细胞调节性疗法设计与可实施性的挑战。
展开英文摘要原文
The development of novel T-cell redirecting immune therapies-including immune checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor T cells, and virus-specific T cells-represents a major advancement in the treatment of haematological malignancies. Although such therapies have strong evidence for efficacy in the treatment of B-cell neoplasms, several unique challenges are encountered when using these therapies for the treatment of T-cell malignancies.
In this Review, we discuss the application of T-cell modulating immune therapies in T-cell neoplasms, with a focus on the complicated bidirectional interactions between malignant and bystander T cells in disease pathogenesis, and the resultant challenges affecting the design and deliverability of T-cell modulating therapies in this cohort.
论文信息
- 作者
- Elliott J、Ritchie D、Koldej R、Khot A
- 单位
- ACRF Translational Research Laboratory, Royal Melbourne Hospital, Melbourne, VIC, Australia; Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Medicine Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia. Electronic address: jessica.elliott@petermac.org.Australia
- 文献类型
- 综述
- 期刊
- The Lancet. Haematology2026 May
- 原文标识
- PubMed 41941875 · DOI 10.1016/S2352-3026(26)00005-0